Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Randomized, Multicenter Phase 2 Trial of Dasatinib (SPRYCEL) vs. Dasatinib Plus Smoothened Antagonist (BMS-833923) in the Treatment of Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia (CML)

Next Previous
Trial Profile

An Open-Label, Randomized, Multicenter Phase 2 Trial of Dasatinib (SPRYCEL) vs. Dasatinib Plus Smoothened Antagonist (BMS-833923) in the Treatment of Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia (CML)

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 08 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BMS 833923 (Primary) ; Dasatinib
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Sponsors Bristol-Myers Squibb

Most Recent Events

  • 05 Oct 2021 This trial has been completed in Spain, according to European Clinical Trials Database record. (2016-01-25)
  • 01 Aug 2017 Results evaluating cardiovascular ischaemic event rates in dasatinib treated patients using patient data from NCT00103701, NCT00101647, NCT00101816, NCT00101660, NCT00101595, NCT00103844, NCT00123474, NCT00123487, NCT00481247, NCT00529763, NCT01357655, NCT00744497 trials and and comparing it with external reference populations published in the Annals of Hematology
  • 24 Jan 2017 Status changed from completed to discontinued.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top